| __timestamp | Gilead Sciences, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 1860000 |
| Thursday, January 1, 2015 | 3426000000 | 2963000 |
| Friday, January 1, 2016 | 3398000000 | 6961000 |
| Sunday, January 1, 2017 | 3878000000 | 11779000 |
| Monday, January 1, 2018 | 4056000000 | 13697000 |
| Tuesday, January 1, 2019 | 4381000000 | 15749000 |
| Wednesday, January 1, 2020 | 5151000000 | 18638000 |
| Friday, January 1, 2021 | 5246000000 | 27196000 |
| Saturday, January 1, 2022 | 5673000000 | 31739000 |
| Sunday, January 1, 2023 | 6090000000 | 33491000 |
| Monday, January 1, 2024 | 6091000000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology, understanding the financial dynamics of industry leaders is crucial. Gilead Sciences, Inc. and Protagonist Therapeutics, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, Gilead Sciences has seen a steady increase in SG&A expenses, rising from approximately $3 billion in 2014 to over $6 billion in 2023, marking a 100% increase. This growth reflects Gilead's expansive market strategies and operational scale.
Conversely, Protagonist Therapeutics, a smaller player, has experienced a more modest rise in SG&A expenses, from under $2 million in 2014 to around $33 million in 2023. This represents a staggering 1,700% increase, indicative of its aggressive growth and market penetration efforts. These trends highlight the diverse strategies employed by biotech companies to navigate the competitive landscape.
Selling, General, and Administrative Costs: Johnson & Johnson vs Gilead Sciences, Inc.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Gilead Sciences, Inc. vs Novavax, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.: SG&A Expense Trends